Neetal Nevrekar, MD

CRS:

BJMC

Role:

Clinical

Position:

Research Clinician

Email:

drneetal24@gmail.com

Dr. Neetal Nevrekar is a research clinician at BJMC-CRS in Pune, India, where she has worked since June 2010. She is experienced in the field of clinical research on HIV, and works on various IMPAACT and ACTG Network research protocols. She worked on research protocols A5207, A5253, and A5225 as a research officer. Presently working on protocols 1077BF and 1077FF (PROMISE), A5282, A5288, and P1078 as a study clinician. 

She screens and enrolls research participants, is involved in developing the source documents for research protocols, and in completing clinical record forms. She is also responsible for adverse event reporting to RSC/DAIDS and for communications with Clinical Managing Committee (CMC) of the respective protocols eith regard to clinical management issues, toxicities, change of study drugs.

Dr. Nevrekar conducts training programs at the site for research staff, counselors and clinical personnel. She has received training in Good Clinical Practices and also completed web based GCP, HSP training. She was a member of Women’s Health Inter-network Scientific Committee (WHISC) for the IMPAACT and ACTG Network.

Dr. Nevrekar received an undergraduate degree from Grant Medical Institute, Mumbai, and a Doctor of Medicine in Obstetrics and Gynaecology from Grant Medical Institute and Bombay Hospital Research Centre. She worked as a senior medical officer at Bombay Hospital Research Centre for four years. Subsequently she was a consultant in Obstetrics and Gynaecology for six years.

  • “Vaginal delivery in a case of Pregnancy with Cervical Fibroid” - Journal of F.I.G.O, vol.49 no.2, page 77 dated April 1999.
  • “A Quadruplet Pregnancy” - Journal of F.I.G.O, vol.57 no.5, page 439-441 dated Sept-Oct. 2007.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More